<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02615080</url>
  </required_header>
  <id_info>
    <org_study_id>RSPR-008</org_study_id>
    <nct_id>NCT02615080</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of CRD007 in Adult Asthma Subjects</brief_title>
  <official_title>A Double-Blind, Randomised, Placebo-controlled, Parallel Group, International, Multi-centre Phase 2 Trial Investigating the Safety and Efficacy of CRD007 in Adult Subjects With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RSPR Pharma AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RSPR Pharma AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomised, placebo-controlled, parallel group, Phase 2 trial
      evaluating CRD007 administered orally b.i.d for 14 weeks for the treatment of asthma. CRD007
      will be given as add on to a background of commonly used controller medication, i.e. inhaled
      corticosteroid (ICS) with or without long-acting beta2-agonist (LABA). By gradually reducing
      the background controller medication, the efficacy and safety of CRD007 will be evaluated on
      top of several dose levels of this medication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present trial will include subjects with diagnosed asthma. The trial involves a total of
      11 visits (Visit 1-2 are screening visits, visit 3 randomisation visit, visits 4-10 treatment
      visits and visit 11 follow-up visit).

      The subjects will be monitored by medically qualified staff every second week at clinic
      visits, where the reduction of their background controller medication will be reduced, if
      their asthma is controlled.

      Between visits to the clinic the subjects have to complete a diary.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 30, 2015</start_date>
  <completion_date type="Actual">February 24, 2017</completion_date>
  <primary_completion_date type="Actual">February 21, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ICS dose</measure>
    <time_frame>Change of average dose of ICS, measured at visit 5 (week 8) and Visit 10 (week 18)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">168</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>CRD007</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CRD007 (containing pemirolast sodium) tablets given twice daily for 14 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo tablets given given twice daily for 14 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CRD007</intervention_name>
    <arm_group_label>CRD007</arm_group_label>
    <other_name>Pemirolast sodium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Age ≥18 years old

          -  Diagnosis of asthma according to Global Initiative for Asthma (GINA) Guidelines

          -  Atopic phenotype as assessed by the investigator

          -  Treated with ICS and LABA for at least 12 weeks prior to Visit 1with protocol defined
             daily doses

          -  Blood eosinophils ≥0.15*109/L at Visit 1

          -  Demonstration of forced expiratory volume at one second (FEV1) &gt;60% of the predicted
             value at Visit 1

          -  Demonstration of ACQ6 ≥ 0.5 and ≤1.5 at Visit 1

          -  Reversibility of at least 12% and 200 mL in FEV1

        Exclusion Criteria:

          -  Lower respiratory tract infection &lt;6 weeks prior to Visit 1

          -  Current smokers

          -  Significant concurrent, uncontrolled medical condition as defined by the protocol

          -  Others, as defined in the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vibeke Backer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MHAT St. Ivan Rilski-2003 Ltd., Department of Internal Medicine</name>
      <address>
        <city>Dupnitsa</city>
        <zip>2600</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHATPPD - Pazardzhik EOOD, Department of phthisiatrics pneumonia and pulmonary functional diagnostics</name>
      <address>
        <city>Pazardzhik</city>
        <zip>4400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center - Razgrad OOD, Office of Pneumonology and Phthisiatry</name>
      <address>
        <city>Razgrad</city>
        <zip>7200</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Smolyan OOD, Office of Clinical Allergology</name>
      <address>
        <city>Smolyan</city>
        <zip>4700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First MHAT - Sofia EAD, Third Department of Internal Medicine</name>
      <address>
        <city>Sofia</city>
        <zip>1000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Lyulin EAD, Department of Internal Medicine</name>
      <address>
        <city>Sofia</city>
        <zip>1336</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHATPPD Vratsa Ltd, Department of Pneumology</name>
      <address>
        <city>Vratza</city>
        <zip>3000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aalborg Universitetshospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bisbebjerg Hospital</name>
      <address>
        <city>København NV</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Næstved Sygehus, Lungemedinsk afdeling</name>
      <address>
        <city>Næstved</city>
        <zip>4700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionshospitalet Silkeborg</name>
      <address>
        <city>Silkeborg</city>
        <zip>8600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Badań Klinicznych PI-House Sp. Z O.O.</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-546</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medica Pro Familia</name>
      <address>
        <city>Katowice</city>
        <zip>40-954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Centrum Medcyczne ProMiMed</name>
      <address>
        <city>Kraków</city>
        <zip>31-637</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medica Pro Familia</name>
      <address>
        <city>Krákow</city>
        <zip>30-002</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Best Solution</name>
      <address>
        <city>Lublin</city>
        <zip>20-045</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ ALERGO-MED. Specjalistyczna Przychodnia Lekarska</name>
      <address>
        <city>Poznan</city>
        <zip>60-823</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medica Pro Familia</name>
      <address>
        <city>Warszawa</city>
        <zip>01-868</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Oporów</name>
      <address>
        <city>Wroclaw</city>
        <zip>52-416</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Medicines Evaluation Unit (MEU) Ltd</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medinova North London Clinical Studies Center</name>
      <address>
        <city>Northwood</city>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medinova East London Clinical Studies Centre</name>
      <address>
        <city>Romford</city>
        <zip>RM1 3LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medinova South London Clinical Studies Centre</name>
      <address>
        <city>Sidcup</city>
        <zip>DA14 6LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Denmark</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2015</study_first_submitted>
  <study_first_submitted_qc>November 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2015</study_first_posted>
  <last_update_submitted>February 24, 2017</last_update_submitted>
  <last_update_submitted_qc>February 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemirolast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

